Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms
Phase 1 – testing safety in a small group of people
Conditions:
Malignant B-cell neoplasms
Sponsor: Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 24 participants
БГ